Eli Lilly’s highly anticipated Alzheimer’s drug has been held back for further review by regulators, the US pharmaceutical giant said Friday, in a blow for patients with the devastating brain disorder.
Eli Lilly’s highly anticipated Alzheimer’s drug has been held back for further review by regulators, the US pharmaceutical giant said Friday, in a blow for patients with the devastating brain disorder.